SCHEMBL20722818

SCHEMBL20722818

CC(C)(C)OC(=O)N1C2CCC1CN(c1cc3c(cn1)C[C@@H](NC(=O)OCc1ccccc1)CO3)C2

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.45
GPR119 Q8TDV5 2/20 0.44
RORC P51449 5/20 0.40
KMT2A Q03164 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
ACHE P22303 2/20 0.39
AGTR2 P50052 1/20 0.38
CTSL P07711 1/20 0.38
CTSB P07858 1/20 0.38
CTSK P43235 1/20 0.38
ALDH1A1 P00352 1/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.37
MAPK1 P28482 1/20 0.37
NTSR1 P30989 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20722820 1.00 HDAC1 (0.45) HDAC1GPR119RORCKMT2AL3MBTL1
SCHEMBL30060044 0.87 BACE1 (0.45) HDAC1GPR119RORCKMT2AL3MBTL1
SCHEMBL30060163 0.87 CTSL (0.41) GPR119RORCKMT2AL3MBTL1CA1
SCHEMBL20722437 0.87 CTSL (0.41) GPR119RORCKMT2AL3MBTL1CA1
SCHEMBL20722630 0.84 KMT2A (0.44) GPR119KMT2AL3MBTL1CA1CA2
SCHEMBL30061522 0.84 KMT2A (0.44) GPR119KMT2AL3MBTL1CA1CA2
SCHEMBL20722514 0.83 GPR119 (0.43) HDAC1GPR119RORCKMT2AL3MBTL1
SCHEMBL20722518 0.83 GPR119 (0.43) HDAC1GPR119RORCKMT2AL3MBTL1
SCHEMBL24730159 0.80 KMT2A (0.39) HDAC1GPR119RORCKMT2AL3MBTL1
SCHEMBL20722616 0.80 KMT2A (0.39) HDAC1GPR119RORCKMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11524966-B1 Carboxamides as ubiquitin-specific protease inhibitors VALO HEALTH, INC. (US) 2022-12-13 US disclosed
US-11524966-B1 Carboxamides as ubiquitin-specific protease inhibitors VALO HEALTH, INC. (US) 2022-12-13 US disclosed
EP-3665169-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS Forma Therapeutics, Inc. (US) 2020-06-17 EP disclosed
WO-2019032863-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS FORMA THERAPEUTICS, INC. (US) 2019-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11524966-B1 Carboxamides as ubiquitin-specific protease inhibitors USP28, USP25, USP24 HDAC1 130/4885GPR119 4020/4885RORC 2899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.